8 assets in Human T-Lymphotropic Virus 1 Infectious Disease

Therapeutic assets addressing Human T-Lymphotropic Virus 1 Infectious Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dolutegravir Human T-Lymphotropic Virus 1 Infectious Disease	Carlos Brites	P2	CCC (53)
Tenofovir Human T-Lymphotropic Virus 1 Infectious Disease	Carlos Brites	P2	CCC (53)
Adriamycin Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Cyclophosphamide Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Etoposide Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Lenalidomide Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Prednisone Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)
Vincristine Sulfate Human T-Lymphotropic Virus 1 Infectious Disease	National Cancer Institute (NCI)	P1	CC (43)